Carcinoid Tumor Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight | Key Companies- Advanced Accelerator Applications S.A., Merck Sharp & Dohme, and Others

Carcinoid Tumor Market Is Expected To Grow During the Forecast Period (2019-2032), DelveInsight | Key Companies- Advanced Accelerator Applications S.A., Merck Sharp & Dohme, and Others

DelveInsight’s Carcinoid Tumor Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Carcinoid Tumor Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).


The Carcinoid Tumor Market report covers emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.


Carcinoid Tumor: Overview

Carcinoid tumors (CT) are a type of slow-growing cancers that can arise in several places throughout the body and are characterized by the production of an excess of hormone-like substances, such as serotonin, bradykinin, histamine, and prostaglandins which leads to the other associated complications. These tumors, are the subset of neuroendocrine tumors and usually begin in the digestive tract (stomach, appendix, small intestine, colon, and rectum) or in the lungs.


Get access to a free copy of our latest sample report @


Some of the key facts of the Carcinoid Tumor Market Report

  • As per the study conducted by Siddiqui et al. titled “The Epidemiology of Carcinoid Tumors of Small and Large Intestine in USA: A National Inpatient Sample Analysis” the malignant CTs of small intestine were the most common out of all CTs of intestine. Interestingly there was male predominance in CTs of small intestine and female predominance in CTs of large intestine.
  • According to a study by Taal et al. titled “Epidemiology of Neuroendocrine Tumours”, the reported incidence of Neuroendocrine tumors was approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites were the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%.
  • According to the study titled “Carcinoid syndrome” conducted by Rehman et al., in Japan, the rate of incidence of carcinoid tumors was 5.25 cases per 100,000 in 2004.


Carcinoid Tumor Market

The Carcinoid Tumor Market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of the Carcinoid Tumor Market in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Carcinoid Tumor Market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Carcinoid Tumor Market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.


Carcinoid Tumor Market Outlook

The current treatment strategies for the effective management of Carcinoid Tumors primarily encompasses the use of approved evidence-based treatments, surgeries, and supportive care services with the ultimate aim of removing or reducing the size of carcinoid tumors and controlling Carcinoid Syndrome symptoms. Furthermore, the treatment plan for each CT affected individual is being tailored on the basis of tumor size, location, symptoms, and growth.


Carcinoid Tumor Treatment Market

In the case of operable carcinoid and hormonally active tumors, surgery with complete removal of all of the tumor tissue is the first choice of treatment, and if the tumor is detected early, surgery can result in a complete and permanent cure. However, even when all tumor tissue cannot be removed, surgery may be necessary for various purposes such as relief of intestinal obstruction or control of intestinal bleeding. When Carcinoid Syndrome is present, removing, or destroying large portions of the tumor (debulking) can effectively diminish the number of harmful hormones being produced and flooding the circulation. Because of the slow growth of most carcinoids, this can relieve symptoms for a long time.


Carcinoid Tumor Epidemiology

The epidemiology section covers insights into the historical and current Carcinoid Tumor Market patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Carcinoid Tumor Market Drugs & Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Carcinoid Tumor Market or expected to get launched in the market during the study period. The analysis covers Carcinoid Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Carcinoid Tumor Market Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies. Unmet needs in the Kaposi’s Sarcoma include therapies that are oral, anthracycline sparing, and deliverable in resource-limited settings. Another major unmet need is the relapse and refractory cases in the patients given treatment with Doxil.


Carcinoid Tumor Market Dynamics

The dynamics of the Carcinoid Tumors (CT) market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and expected the launch of emerging therapies during the forecast period of 2020-2030.


Carcinoid Tumor Emerging Therapies

Companies across the globe are thoroughly working toward the development of new treatment therapies for CT. Some of the key players in the therapeutic market of CT at a global level are Bristol-Myers Squibb, Merck Sharp & Dohme, Exelixis, and others. Some of the products which are currently in mid and late phase of clinical development include Pembrolizumab (Merck Sharp & Dohme), Nivolumab (Bristol-Myers Squibb), Cabozantinib in different combinations (Exelixis), etc.


Carcinoid Tumor Companies

  • Advanced Accelerator Applications S.A.
  • Merck Sharp & Dohme
  • Exelixis/Bristol-Myers Squibb, and Others


Carcinoid Tumor Drugs

  • Lutathera
  • Pembrolizumab
  • Nivolumab + Cabozantinib, and others


Table of content

  1. Key Insights
  2. Executive Summary
  3. Competitive Intelligence Analysis
  4. Market Overview at a Glance
  5. Disease Background and Overview
  6. Patient Journey
  7. Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Carcinoid Tumor Market Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight


Consult with our Business Expert @


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States